Citigroup analyst issues MARKET OUTPERFORM recommendation for DBVT on September 30, 2026 08:16AM ET. The previous analyst recommendation was Market Outperform.DBVT was trading at $11.55 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 10 - Buy, 4 - Hold, 1 - Sell recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport...
Andrea Newkirk from Goldman Sachs issued a price target of $103.00 for KOD on 2026-09-30 01:00:16.The...
Goldman Sachs analyst issues NEUTRAL recommendation for KOD on September 30, 2026 01:00AM ET. The previous...
Vaxart, Inc. (VXRT) closed at $0.4578 on 124,977 shares, -0.4% on the session.The close landed 89%...
By KlickAnalytics Data InsightsSeptember 29, 2026 · 4:00 PM ETAldeyra The moved sharply in the latest...
Andrea Newkirk from Goldman Sachs issued a price target of $103.00 for KOD on 2026-09-30 01:00:16.The adjusted price target was set to $103.00.At the time of the announcement, KOD was...
from Stifel Nicolaus issued a price target of $18.00 for ACHV on 2026-09-29 20:15:49.The adjusted price target was set to $18.00.At the time of the announcement, ACHV was trading at...
Eric Stine from Craig-Hallum issued a price target of $7.00 for HYLN on 2026-09-29 11:48:00.The adjusted price target was set to $7.00.At the time of the announcement, HYLN was trading...
from Maxim Group issued a price target of $6.00 for APYX on 2026-09-29 11:44:58.The adjusted price target was set to $6.00.At the time of the announcement, APYX was trading at...
Michael Yee from UBS issued a price target of $120.00 for KOD on 2026-09-29 10:13:55.The adjusted price target was set to $120.00.At the time of the announcement, KOD was trading...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
